BIOCON Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > biocon

Technical Analysis

Technical Strength: 3 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 36.1. According to RSI analysis, biocon is weak. 3.0 BIOCON RSI Chart
MACD (?) MACD: -9.99 and Signal Line: -3.93. According to MACD analysis, biocon is technically weak. 2.0 BIOCON MACD Chart
Simple Moving Average (?) According to simple moving average analysis, biocon is in a downtrend. Resistance level is at 342. 1.0 BIOCON Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, biocon is in a downtrend. Resistance level is at 335. 1.0 BIOCON Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.163. According to bollinger bands, biocon is technically weak. 3.0 BIOCON Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is below all levels. Resistance levels are 363.0832, 377.55 and 392.0168. Support is at 316.25. 7.0 BIOCON Fibonacci Retracement Chart
Average True Range (?) ATR: 16.6 NA BIOCON Average True Range Chart
Average Directional Index (?) ADX is 30.4 which means BIOCON is in a trend. NA BIOCON Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
August 18, 2017
Open Price 329.0
High Price 331.85
Low Price 324.2
Close Price 328.95
Absolute Change 0.55
Percentage Change 0.167%
Weekly Change -0.649%
Monthly Change -18.3%
Yearly Change 16.5%
52-week high 438.85
52-week low 268.133333333
Corporate Actions
ExDate Purpose
July 20, 2017 AGM/DIV-RE 1 PER SHARE
June 15, 2017 BONUS 2:1
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.753
Confidence in Beta5.31%
Market Capital Rs. 6578.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 14.5566666667
TTM Price-to-Earnings (P/E) Ratio 22.6
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 18 August 2017: Deliverable Quantity:4.95e+05 NA BIOCON Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 18 August 2017: Daily Volatility:0.5693 NA BIOCON Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 18 August 2017: PCR_OI:0.404 PCR:0.531 NA BIOCON PCR Chart
Option Pain (?) 18 August 2017: Max Pain:340.0 NA BIOCON Option Pain Chart
Premium (?) 18 August 2017 Premium: 0.75 Futures OI:10515600.0 NA BIOCON Premium Chart
Option_MAX_OI (?) 18 August 2017: Price:328.95 Put with maximum OI:300.0 Call with maximum OI:400.0 NA BIOCON Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
August 31, 2017 329.7 10515600.0 2497.0 2645.0 328.95
September 28, 2017 331.1 1368000.0 118.0 124.0 328.95
October 26, 2017 332.7 16200.0 1.0 1.0 328.95


August 17, 2017 BiocAnalysts/Institutional Investor Meet/Con. Call Updatescon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
August 16, 2017 BiocPress Releasecon Limited has informed the Exchange regarding a press release dated August 16, 2017, titled "Company Statement on Status of EMA Dossiers.".
See all Announcements

Board Meetings

Date Meeting Date Purpose
June 30, 2017 July 27, 2017 inteResults/Otherser alia, to consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended June 30, 2017 amongst other routine matters.
April 25, 2017 April 27, 2017 The Results/Dividend/Bonus Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on April 27, 2017 inter alia, to consider, approve and take on record, the audited financial results (both standalone and consolidated) of the Company for the year ended March 31, 2017 amongst other routine matters recommendation of final dividend , if any , for the financial year 2016-17. The Company has now informed the Exchange that the board to consider and recommend to issue bonus share.(purpose revised).
See all Board Meetings

BIOCON is part of...

Index Weightage

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 317.2 Rs. 320.7 Rs. 324.8 Rs. 328.3 Rs. 332.5 Rs. 336 Rs. 340.1